P Trimoulet

Summary

Affiliation: CHU de Bordeaux
Country: France

Publications

  1. ncbi request reprint Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy
    Pascale Trimoulet
    Laboratoire de Virologie, CHU de Bordeaux, Bordeaux, France
    Antivir Ther 18:723-7. 2013
  2. pmc Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study
    Vincent Thibault
    Pitie Salpetriere, Paris, France
    Virol J 10:87. 2013
  3. doi request reprint Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples?
    Pascale Trimoulet
    Laboratoire de Microbiologie Fondamentale et Pathogénicité UMR 5234, Centre Hospitalier Universitaire CHU et Université Bordeaux Ségalen, Hopital Pellegrin, Bordeaux, France
    J Virol Methods 181:131-3. 2012
  4. pmc Estimation of dynamical model parameters taking into account undetectable marker values
    Rodolphe Thiebaut
    INSERM E0338 Biostatistics, Bordeaux 2 University, Bordeaux, France
    BMC Med Res Methodol 6:38. 2006
  5. ncbi request reprint Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy
    Pascale Trimoulet
    Laboratoire de Virologie, Centre Hospitalier Universitaire, Hopital Pellegrin, Bordeaux Cedex, France
    J Med Virol 72:46-51. 2004
  6. doi request reprint Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients
    P Trimoulet
    Virology Laboratory, Bordeaux University Hospital, France
    HIV Med 12:506-9. 2011
  7. ncbi request reprint Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004
    Pascale Trimoulet
    Laboratoire de virologie Hôpital Pellegrin, 33076 Bordeaux Cedex
    Gastroenterol Clin Biol 31:1088-94. 2007
  8. pmc Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum
    Pascale Trimoulet
    Laboratoire de Virologie, Centre Hospitalier Régional et Université Victor Segalen, CHU de Bordeaux, Bordeaux, France
    J Clin Microbiol 40:2031-6. 2002
  9. ncbi request reprint Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection
    P Trimoulet
    Laboratoire de Virologie, Centre Hospitalo Universitaire, Bordeaux, France
    J Med Virol 67:143-51. 2002
  10. ncbi request reprint Impact of protease inhibitors on intrahepatic hepatitis C virus viral load
    D Neau
    , Centre Hospitalo-Universitaire Pellegrin, Bordeaux, France
    AIDS 15:1736-8. 2001

Detail Information

Publications33

  1. ncbi request reprint Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy
    Pascale Trimoulet
    Laboratoire de Virologie, CHU de Bordeaux, Bordeaux, France
    Antivir Ther 18:723-7. 2013
    ..Telaprevir (TVR) is a protease inhibitor (PI) used in chronic hepatitis C treatment with pegylated interferon plus ribavirin. We analysed the prevalence and kinetic development of TVR resistance upon treatment...
  2. pmc Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study
    Vincent Thibault
    Pitie Salpetriere, Paris, France
    Virol J 10:87. 2013
    ....
  3. doi request reprint Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples?
    Pascale Trimoulet
    Laboratoire de Microbiologie Fondamentale et Pathogénicité UMR 5234, Centre Hospitalier Universitaire CHU et Université Bordeaux Ségalen, Hopital Pellegrin, Bordeaux, France
    J Virol Methods 181:131-3. 2012
    ..0001). This study shows that using the same assay in multicenter trials and cohorts is still relevant due to inter-assay differences observed in HCV plasma load measurements...
  4. pmc Estimation of dynamical model parameters taking into account undetectable marker values
    Rodolphe Thiebaut
    INSERM E0338 Biostatistics, Bordeaux 2 University, Bordeaux, France
    BMC Med Res Methodol 6:38. 2006
    ..A method is proposed to take into account left-censored values for estimating parameters of non linear mixed models and its impact is demonstrated through a simulation study and an actual clinical trial of anti-HCV drugs...
  5. ncbi request reprint Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy
    Pascale Trimoulet
    Laboratoire de Virologie, Centre Hospitalier Universitaire, Hopital Pellegrin, Bordeaux Cedex, France
    J Med Virol 72:46-51. 2004
    ..Nonresponse can be predicted as early as week 4 or week 12 in nonresponders treated with daily IFN and ribavirin...
  6. doi request reprint Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients
    P Trimoulet
    Virology Laboratory, Bordeaux University Hospital, France
    HIV Med 12:506-9. 2011
    ..The aim of this study was to describe the natural prevalence of mutations conferring resistance to HCV PIs in HIV/HCV-coinfected patients compared with HCV-monoinfected patients...
  7. ncbi request reprint Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004
    Pascale Trimoulet
    Laboratoire de virologie Hôpital Pellegrin, 33076 Bordeaux Cedex
    Gastroenterol Clin Biol 31:1088-94. 2007
    ..To determine the prevalence of HBV genotypes in Southwestern France and the association between HBV genotypes and patients characteristics...
  8. pmc Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum
    Pascale Trimoulet
    Laboratoire de Virologie, Centre Hospitalier Régional et Université Victor Segalen, CHU de Bordeaux, Bordeaux, France
    J Clin Microbiol 40:2031-6. 2002
    ..03 to 0.14. The bDNA 3.0 assay results were positively correlated with the bDNA 2.0 assay results (r = 0.9533). Taking in account the overall performance, this assay could be used as a routine tool for the HCV RNA quantification...
  9. ncbi request reprint Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection
    P Trimoulet
    Laboratoire de Virologie, Centre Hospitalo Universitaire, Bordeaux, France
    J Med Virol 67:143-51. 2002
    ..The immune improvement associated with PI regimens could help reduce HCV load, supporting a protective effect of PI-induced immune restoration...
  10. ncbi request reprint Impact of protease inhibitors on intrahepatic hepatitis C virus viral load
    D Neau
    , Centre Hospitalo-Universitaire Pellegrin, Bordeaux, France
    AIDS 15:1736-8. 2001
    ..However, a decrease in HCV plasma load was recently described in patients treated with HAART for a year [9,10]. We therefore investigated the potential impact of HAART on intrahepatic HCV load...
  11. pmc The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010
    Marc Arthur Loko
    INSERM, U897 and ISPED, Universite Victor Segalen, Bordeaux, France
    BMC Infect Dis 10:303. 2010
    ..The ANRS CO 13 HEPAVIH cohort was set up to explore these critical questions.To describe the cohort aims and organization, monitoring and data collection procedures, baseline characteristics, as well as follow-up findings to date...
  12. doi request reprint Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C
    D Breilh
    Laboratoire de Pharmacocinétique et de Pharmacie Clinique EA2968, Universite Victor Segalen Bordeaux 2, Bordeaux, France
    Aliment Pharmacol Ther 30:487-94. 2009
    ..The main goal of therapy in hepatitis C virus (HCV) infection is to achieve a sustained virological response (SVR). However, the impact of the pharmacological properties of ribavirin on the SVR has not been fully investigated...
  13. ncbi request reprint Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C
    Victor de Ledinghen
    Service d Hepato Gastroenterologie, Centre Hospitalier Universitaire, Pessac, France
    J Hepatol 36:672-80. 2002
    ..We compared the efficacy and safety of daily interferon alfa-2b in combination with ribavirin with those of interferon alfa-2b three times a week alone or in combination with ribavirin...
  14. ncbi request reprint [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up]
    M Seydi
    Service de Medecine Interne et Maladies Infectieuses, Hôpital Saint André, 1, rue Jean Burguet, CHU de Bordeaux, 33075 Bordeaux cedex, France
    Rev Med Interne 26:280-7. 2005
    ..To describe efficacy and safety in clinical practice of pegylated interferon plus ribavirin (INFpeg-Riba) in the treatment of hepatitis C viral infection (HCV) in HIV infected patients...
  15. ncbi request reprint Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study
    C Payan
    Laboratoire de Virologie, CHU Angers, France
    J Viral Hepat 12:405-13. 2005
    ..The modification of the HCV genotype pattern in France in the next 10 years may require new therapeutic strategies, and further survey studies...
  16. ncbi request reprint HIV and HCV co-infection: situation at six French university hospitals in the year 2000
    Claudine Buffet-Janvresse
    Laboratoire de Virologie, Universite de Rouen, Rouen, France
    J Med Virol 69:7-17. 2003
    ..In conclusion, despite the difficulties in managing hepatitis C in HIV-infected patients, almost one-half of all patients in this study had received anti-HCV treatment...
  17. ncbi request reprint Epidemiological and phylogenetic evidence for patient-to-patient hepatitis C virus transmission during sclerotherapy of varicose veins
    Victor de Ledinghen
    Services d Hépato gastroentérologie, Centre Hospitalier Universitaire, Bordeaux, France
    J Med Virol 76:279-84. 2005
    ..The method by which infection was likely to have been transmitted was probably the use of a single vial for multiple patients. This study provides strong evidence that sclerotherapy of varicose veins is a risk factor for HCV infection...
  18. doi request reprint Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy
    Florence Legrand-Abravanel
    Laboratoire de Virologie, Centre Hospitalier Universitaire, Toulouse, France
    J Med Virol 81:2029-35. 2009
    ..0-2.5; P = 0.04) or subtypes 4a and 4d (OR: 2.03; 95% CI = 1.1-3.8; P = 0.03). In conclusion, among difficult-to-treat genotypes, the subtype 1a is associated with a lower response to anti-HCV therapy than subtypes 1b, 4a, and 4d...
  19. ncbi request reprint Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype
    L Castera
    Department of Hepatology, Hopital Haut Leveque, Centre Hospitalier Universitaire Bordeaux, Pessac, France
    Aliment Pharmacol Ther 26:1489-98. 2007
    ..Significance of steatosis in HIV-HCV coinfection remains controversial...
  20. ncbi request reprint Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients
    Didier Neau
    Virology Laboratory, University of Victor Segalen, Bordeaux, France
    J Med Virol 71:41-8. 2003
    ..In conclusion, in HIV-infected patients, HCV variability had no significant influence on virological response to anti-HCV treatment...
  21. ncbi request reprint Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years)
    Victor de Ledinghen
    Service d Hepato Gastroenterologie, Hopital Haut Leveque, Pessac, France
    J Hepatol 46:19-25. 2007
    ....
  22. ncbi request reprint Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone
    Victor de Ledinghen
    Service d Hepato Gastroenterologie, Centre Hospitalier Universitaire, Hopital du Haut leveque, 33604 Pessac Cedex, France
    J Hepatol 36:819-26. 2002
    ....
  23. ncbi request reprint Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients
    Didier Neau
    Fédération des Maladies Infectieuses, Centre Hospitalo Universitaire Pellegrin, Bordeaux, France
    Clin Infect Dis 36:1564-71. 2003
    ..In conclusion, the combination of conventional IFN-alpha-2a and ribavirin has poor virological efficacy in HCV-HIV-coinfected patients...
  24. ncbi request reprint PCR-detected hepatitis C virus RNA associated with human zona-intact oocytes collected from infected women for ART
    A Papaxanthos-Roche
    Laboratoire de Biologie de la Reproduction, maternité Pellegrin, Centre Hospitalier Universitaire, Hopital Pellegrin, Bordeaux, France
    Hum Reprod 19:1170-5. 2004
    ..The aim of this study was to investigate the susceptibility of human oocytes from hepatitis C virus (HCV) RNA-positive women to HCV contamination during assisted reproductive technology (ART)...
  25. doi request reprint Hepatitis E virus infection as a new probable cause of de novo membranous nephropathy after kidney transplantation
    B Taton
    Nephrology Transplantation, CHU de Bordeaux, Bordeaux, France
    Transpl Infect Dis 15:E211-5. 2013
    ..The chronology of the onset and remission of both diseases is highly suggestive of a causal relationship between hepatitis E and MN...
  26. ncbi request reprint New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients
    I Pellegrin
    Laboratoire de Virologie, Centre Hospitalier Régional Hôpital Pellegrin, Place Amelie Raba Leon, 33 076 Bordeaux Cedex, France
    J Infect Dis 182:36-42. 2000
    ..PBL assays appear to be more appropriate than plasma assays when pre-emptive therapy is required to prevent the rapid progression from the first detection of the virus to CMV disease...
  27. ncbi request reprint Seven nucleotide changes characteristic of the hepatitis C virus genotype 3 5' untranslated region: correlation with reduced in vitro replication
    Cyril Masante
    UMR 5234 CNRS, IFR66, Universite Victor Segalen Bordeaux 2, 146, rue Leo Saignat, 33076 Bordeaux Cedex, France
    J Gen Virol 89:212-21. 2008
    ..Nucleotides 13, 14 and 224 were found to be responsible for this effect. Moreover, a reduced replicative activity was confirmed ex vivo for genotype 3, but to a lesser extent than that observed in vitro, using an RNA minigenome...
  28. ncbi request reprint Fibrosis is worse in HIV-HCV patients with low-level immunodepression referred for HCV treatment than in HCV-matched patients
    Anne Rullier
    Department of Pathology, Bordeaux Hospital, Bordeaux, France
    Hum Pathol 35:1088-94. 2004
    ..Our data confirm the need to treat such patients against HCV, and suggest that HIV infection could favor fibrosis via the modulation of the intrahepatic immune response...
  29. doi request reprint Evolution of plasma hepatitis C virus load in patients coinfected by HIV and hepatitis C Virus started on a protease inhibitor-containing antiretroviral regimen, Agence Nationale de Recherches sur le SIDA CO8 APROCO-COPILOTE cohort
    Didier Neau
    J Acquir Immune Defic Syndr 48:227-9. 2008
  30. pmc Multicenter trials need to use the same assay for hepatitis C virus viral load determination
    Syria Laperche
    Centre National de Référence pour les Hépatites B et C en Transfusion, Département des Agents Transmissibles par le Sang, Institut National de la Transfusion Sanguine, 6 rue Alexandre Cabanel, 75015, Paris, France
    J Clin Microbiol 45:3788-90. 2007
    ..This underlines the importance of using the same assay in multicenter studies or when monitoring antiviral therapy...
  31. pmc Plasma and liver hepatitis C virus variability in patients coinfected with human immunodeficiency virus
    Anne Christine Jouvencel
    Laboratoire de Virologie EA2968, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux, France
    J Clin Microbiol 44:1877-80. 2006
    ..In the patients coinfected with HIV, accumulated random mutations produced mostly nonsynonymous substitutions in contrast to the reduced HCV genetic variability seen after treatment...
  32. ncbi request reprint CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment
    Elisabeth Legrand
    Virology Laboratory, Bordeaux 2 University, France
    J Infect Dis 186:302-11. 2002
    ..These findings suggest that HCV genotype may influence specific immune response, which, in turn, is implicated in virologic control...
  33. ncbi request reprint Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients
    Yves Benhamou
    Service d Hepato Gastroenterologie, Hopital Pitie Salpetriere, Paris, France
    Hepatology 43:548-55. 2006
    ..In conclusion, this retrospective analysis demonstrates the efficacy of TDF against wild-type, presumed precore mutants and LAM-resistant HBV when used as a part of anti-retroviral therapy in HIV-coinfected patients...